TG Therapeutics Shares Drop 37% After FDA Imposes Partial Clinical Hold
January 27 2022 - 1:46PM
Dow Jones News
By Denny Jacob
Shares of TG Therapeutics Inc. fell nearly 37% to $8.75 Thursday
after the company disclosed in a regulatory filing that the Food
and Drug Administration imposed a partial clinical hold on select
studies of one of its treatments.
According to the regulatory filing, Chief Executive Michael
Weiss told an investor conference that the partial clinical hold
wasn't based on based on any new information the company provided
but appeared to be based on the same data and concerns that led to
a previously announced Oncologic Drug Advisory Committee meeting,
which is set to take place in either March or April. No new
patients may be enrolled to the select chronic lymphocytic leukemia
and non-Hodgkin's lymphoma studies identified by the FDA as a
result of the partial hold, he said.
Trading in TG Therapeutics was paused for volatility at 10:21
a.m. ET and resumed five minutes later.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
January 27, 2022 13:31 ET (18:31 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.